Acupuncture modulates the microbiota-gut-brain axis in IBS: a mechanistic exploration
This narrative review proposes a mechanistic framework for acupuncture acting on the microbiota-gut-brain axis in IBS, but provides no primary data or quantitative analysis to support clinical efficacy.
| Population | IBS patients (any subtype), with reference to animal models and mechanistic studies |
|---|---|
| Intervention | Acupuncture (primarily at ST36) focusing on microbiota-gut-brain axis modulation |
| Comparator | Not applicable — narrative review without formal comparator |
| Outcome | Gut microbiota composition; Visceral hypersensitivity; Intestinal permeability (tight junction proteins); HPA axis activity (cortisol, CRH, ACTH); Neuroinflammation (TNF-α, IL-6, IL-1β, NF-κB); SCFA production (butyrate); IBS clinical outcomes (abdominal pain, bowel habits) |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Gut microbiota composition | not reported — narrative synthesis only, in the quantitative data | — | Very low | — | |
| Visceral hypersensitivity | not reported — mechanistic proposal only, in the quantitative data | — | Very low | — | |
| Intestinal permeability (tight junction proteins) | not reported — narrative synthesis only, in the quantitative data | — | Very low | — | |
| HPA axis activity (cortisol, CRH, ACTH) | not reported — mechanistic proposal only, in the quantitative data | — | Very low | — | |
| Neuroinflammation (TNF-α, IL-6, IL-1β, NF-κB) | not reported — narrative synthesis only, in the quantitative data | — | Very low | — | |
| SCFA production (butyrate) | not reported — mechanistic proposal only, in the quantitative data | — | Very low | — | |
| IBS clinical outcomes (abdominal pain, bowel habits) | not reported — in the primary clinical data presented | — | Very low | — |
Context
IBS affects approximately 9.2% of the global population and lacks well-established disease-modifying treatments. Microbiota-gut-brain axis dysfunction is considered a central mechanism. Acupuncture is used clinically, but its mechanisms of action remain speculative.
What the study showed
The paper synthesizes indirect evidence that acupuncture may remodel gut microbiota composition, increase SCFA production (e.g., butyrate), reduce circulating LPS, restore tight junction proteins (ZO-1, Occludin, Claudin-1), suppress TLR4/NF-κB signaling, and normalize HPA axis hyperactivity. No primary data, effect sizes, 95% CIs, or meta-analyses are presented. All findings are qualitative descriptions of heterogeneous cited studies without quantitative synthesis.
How it was done
Narrative review published in Frontiers in Neuroscience (2026). No registered protocol, explicit inclusion/exclusion criteria, systematic search strategy, risk-of-bias assessment (AMSTAR-2 not applied), or quantitative synthesis. Total sample size is not stated.
Effect magnitude
No effect size calculated. The paper presents no RR, OR, SMD, MD, or 95% CI for any outcome. The magnitude of effects attributed to acupuncture is indeterminate.
Risk of bias
Narrative review without systematic methodology — high risk of selection and confirmation bias. No formal quality assessment of included studies (AMSTAR-2 not applied). Indiscriminate mixing of animal model data, in vitro studies, and clinical trials without evidence-level separation by outcome. Causal directionality between acupuncture, microbiota, and IBS symptoms is not established.
What this study does NOT prove
This study does NOT prove that acupuncture is effective for IBS, nor that it causally modulates the microbiota-gut-brain axis in humans. It does not permit clinical generalization or establish causality.
In clinical practice
This article does not provide sufficient basis to change clinical practice. Clinicians should rely on systematic reviews and RCTs for decisions on acupuncture in IBS. The proposed mechanistic framework may guide future research hypotheses but does not replace controlled clinical evidence.
Limitations
Narrative review without systematic methodology — high risk of selection and confirmation bias. No formal quality assessment of included studies (AMSTAR-2 not applied). Indiscriminate mixing of animal model data, in vitro studies, and clinical trials without evidence-level separation by outcome. Causal directionality between acupuncture, microbiota, and IBS symptoms is not established.
What is still missing
RCTs with acupuncture versus sham acupuncture and versus standard treatment arms, with direct microbiota, intestinal permeability, and validated clinical outcome measures. Dose-response studies and identification of specific microbial metabolites mediating observed effects.
Technical appendix
Version history
- 1.0 · 2026-06-26 — Auto-generated under Evidence Standard v1.0